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Abstract
This document is an executive summary of the APSIC Guide for Prevention of Central Line Associated Bloodstream
Infections (CLABSI). It describes key evidence-based care components of the Central Line Insertion and Maintenance
Bundles and its implementation using the quality improvement methodology, namely the Plan-Do-Study-Act
(PDSA) methodology involving multidisciplinary process and stakeholders. Monitoring of improvement over time
with timely feedback to stakeholders is a key component to ensure the success of implementing best practices. A
surveillance program is recommended to monitor outcomes and adherence to evidence-based central line
insertion and maintenance practices (compliance rate) and identify quality improvement opportunities and
strategically targeting interventions for the reduction of CLABSI.
Keywords: Central line associated bloodstream infections, CLABSI, Insertion bundle, Maintenance bundle, Quality
improvement
Background
Central line–associated bloodstream infections, or CLAB-
SIs, are associated with increased morbidity, mortality,
and health care costs [1]. It is now recognized that CLAB-
SIs are largely preventable when evidence based guidelines
are followed for the insertion and maintenance of Central
Venous Catheters (CVC) [2]. The intent of this document
is to highlight practical recommendations in a concise for-
mat designed to assist healthcare settings in the Asia Pa-
cific region in implementing CLABSI prevention efforts.
This document is a summary of the CLABSI prevention
guidelines developed by the Asia Pacific Society of Infec-
tion Control (APSIC).
The term “central line” used in the guidelines is
defined as an intravascular access device or catheter that
terminates at or close to the heart or in one of the great
vessels. The following are considered great vessels for
the purpose of defining a central line; pulmonary artery,
superior vena cava, inferior vena cava, brachiocephalic
veins, internal jugular veins, subclavian veins, external
iliac veins, common iliac veins or femoral veins. A hol-
low introducer is considered a central line if the tip is
situated in a great vessel. The line may be used for infu-
sion, or hemodynamic monitoring. Examples include a
central venous catheter for infusion, pulmonary artery
(PA) catheter, sheath/introducer for a PA catheter, dialy-
sis or hemofiltration catheter in a great vessel and a
peripherally inserted central catheter (PICC). A central
line may be inserted centrally or peripherally (PICC) in a
patient. Neither the location of the insertion site nor the




APSIC convened Infection Prevention and Control
experts from the Asia Pacific region to develop the
APSIC Guide for Prevention of Central Line
Associated Bloodstream Infections (CLABSI). The
members of this workgroup comprising key
opinion leaders from the Asia Pacific region are
the authors of this paper.
2. Literature Review and Analysis
For the APSIC guideline, the workgroup reviewed
previously published guidelines and
recommendations relevant to each section and
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performed computerized literature searches using
PubMed on keywords including CLABSI, CA-BSI,
CR-BSI, Asia Pacific and guideline.
3. Process
The workgroup met face to face on two occasions
in addition to email correspondence to complete
the development of the guideline. Discussion was
also focused on how best to integrate the evidence
in the Asia Pacific setting. Criteria for grading the
strength of recommendations and quality of
evidence are described in Table 1. Systematic
review of existing guidelines was undertaken in
addition to review of studies from the Asia Pacific
region [3–14]. Expert consensus on selection of
recommendations and strength of
recommendations was obtained from the
workgroup to develop the draft, which was then
submitted to APSIC Executive Committee and
national Infection Control societies in the Asia
Pacific region. Comments obtained were then
reviewed by the workgroup for necessary edits,
following by final approval and endorsement by
the APSIC Executive Committee and national
societies from the Asia Pacific region.
4. Recommendations for insertion
A. The Central Line Insertion Bundle
1. Optimal site selection
2. Hand hygiene
3. Alcohol-based chlorhexidine skin preparation
4. Maximum barrier precautions
Optimal site selection [15–18]
The catheter insertion site affects the risk for catheter-
related infection and phlebitis. The risk for catheter in-
fection in part can be related to the risk for thrombo-
phlebitis and the density of local skin flora. Femoral
catheters are associated with a higher risk of infection
and deep venous thrombosis, than internal jugular or
subclavian catheters and should also be avoided, where
possible. A subclavian site is preferred in adult patients
and factors such as potential for mechanical complica-
tions and risk for subclavian vein stenosis, should be
considered when determining the catheter insertion site.
1. Select catheter type and insertion site on the basis of
intended purpose and duration of use, risk of
infectious and non-infectious complications (e.g.,
phlebitis and infiltration), and the skills and training
of individuals inserting and caring for the central
venous catheters. (IB)
2. Use a midline catheter or peripherally inserted
central catheter (PICC), instead of a short peripheral
catheter, when the duration of IV therapy will likely
exceed six days. (IB)
3. Recommendations for central venous catheters
a. Weigh the risk and benefits of placing a central
venous device at a recommended site to reduce
infection against the risk of mechanical
complications (e.g., pneumothorax, subclavian
artery puncture, subclavian vein laceration,
subclavian vein stenosis, hemothorax, thrombosis,
air embolism, and catheter misplacement). (IA)
b. Avoid using the femoral vein for central venous
access (I)
c. No recommendation can be made for a preferred
site of insertion to minimize infection risk for a
tunneled CVC. (UI Unresolved issue)
d. Place catheters used for short term hemodialysis and
pheresis in a jugular or femoral vein, rather than a
subclavian vein, to avoid venous stenosis. (IA)
e. Use ultrasound guidance when available to place
central venous catheters to reduce the number of
cannulation attempts and mechanical
complications. (IB)
Hand hygiene [19, 20]
Hand hygiene before catheter insertion or maintenance,
combined with proper aseptic technique during catheter
manipulation and care, provides protection against
infection.
1. Hand hygiene should be performed before and
after palpating catheter insertion sites as well as
before and after inserting, replacing, accessing,
repairing, or dressing an intravascular catheter
Table 1 Categories for strength of each recommendation
Categories for strength of each recommendation
Category Definition
A Good evidence to support a recommendation for use.
B Moderate evidence to support a recommendation for use.
C Insufficient evidence to support a recommendation for or
against use
D Moderate evidence to support a recommendation against
use.
E Good evidence to support a recommendation against use.
Categories for quality of evidence on which recommendations are
made
Grade Definition
I Evidence from at least one properly randomized, controlled
trial.
II Evidence from at least one well-designed clinical trial without
randomization, from cohort or case-controlled analytic studies,
preferably from more than one centre, from multiple time
series, or from dramatic results in uncontrolled experiments.
III Evidence from opinions of respected authorities on the basis
of clinical experience, descriptive studies, or reports of expert
committees.
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site. Palpation of the insertion site should not be
performed after the application of antiseptic,
unless aseptic technique is maintained. (IB)
2. Maintain aseptic technique for the insertion and care
of intravascular catheters. (IB)
3. Sterile gloves should be worn for the insertion of
arterial, central, and midline catheters. (IA)
4. Use new sterile gloves before handling the new catheter
when guidewire exchanges are performed. (II)
5. Wear either clean or sterile gloves when changing the
dressing on intravascular catheters. (IC)
Alcohol-based chlorhexidine skin preparation [21, 22]
While alcohol-based chlorhexidine has become a standard
antiseptic for skin preparation for the insertion of both
central and peripheral venous catheters, alternatives may
need to be used where there is a contraindication.
1. Prepare and clean the skin site with an alcoholic
chlorhexidine solution containing a concentration
of 0.5 to 2 % chlorhexidine and 70 % alcohol
before central venous catheter insertion and during
dressing changes. If there is a contraindication to
chlorhexidine (e.g. hypersensitivity), tincture of
iodine, an iodophor, or 70 % alcohol can be used as
alternatives. (IA)
2. No recommendation can be made for the safety or
efficacy of chlorhexidine in infants aged <2 months.
(UI, unresolved issue).
3. Allow the skin antiseptic being used to dry
completely before catheter insertion. (IB)
4. Disinfect catheter hubs, needleless connectors, taps
and injection ports before accessing the catheter using
an alcoholic chlorhexidine preparation or 70 %
alcohol. (IIB)
Maximum barrier precautions [23]
These refer to the wearing a sterile gown, sterile gloves,
mask and a cap along with the use of a full body sterile
drape to cover the patient (similar to the sterile drapes
used in the operating room) during the insertion of cen-
tral venous catheters.
1. Use maximal sterile barrier precautions during
insertion of central venous catheters, (IB)
2. Use a sterile sleeve to protect pulmonary artery
catheters during insertion. (IB)
B. Central line maintenance bundle components [24–35]
CLABSI maintenance bundle components include:-
1. Daily review of line necessity and replacement
2. Hand hygiene
3. Disinfection of hubs
4. Strict aseptic technique for dressing changes
5. Standardize administration sets changes
Daily review of line necessity and replacement
The central venous catheters should be reviewed daily
for ongoing need. This is because the risk of CLABSIs
increases with the duration of time the catheter is left in
place, so daily evaluation of central lines is an important
aspect of CLABSI prevention. Catheters that are no lon-
ger needed should be promptly removed.
To minimize the risk of infection:
1. Designate only trained personnel who have
demonstrated competency in the insertion and
maintenance of central intravascular catheters. (IA)
2. Promptly remove any central venous catheter that is
no longer required. (IA)
3. Ensure appropriate nursing staff levels in ICUs.
Observational studies suggest that a higher
proportion of “pool nurses” or an elevated patient–to-
nurse ratio is associated with increased CRBSI in
ICUs. (IB)
4. Promptly remove any intravascular catheter that is
no longer required (IA)
5. When adherence to aseptic technique cannot be
ensured (i.e. catheters inserted during a medical
emergency), replace the catheter as soon as possible,
i.e. within 48 hours. (IB)
6. Do not routinely replace CVCs, PICCs, hemodialysis
catheters, or pulmonary artery catheters. (IB)
7. Do not remove CVCs or PICCs on the basis of fever
alone. Use clinical assessment to determine if
infection is evidenced elsewhere or if there is another
non-infectious cause of the fever. (II)
8. Do not routinely change CVCs over guidewire
exchanges for non-tunneled catheters. (IB)
9. Do not use guidewire exchanges to replace a non-
tunneled catheter suspected of infection. (IB)
10.Use a guidewire exchange to replace a
malfunctioning non-tunneled catheter if there is no
evidence of infection is present. (IB)
Hand hygiene, glove use and aseptic technique
1. Use new sterile gloves and aseptic technique before
handling the new catheter when guidewire exchanges
are performed. (II)
2. Hand hygiene should be performed before and after
palpating catheter insertion sites as well as before
and after inserting, replacing, accessing, repairing, or
dressing an intravascular catheter. Palpation of the
insertion site should not be performed after the
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application of antiseptic, unless aseptic technique is
maintained. (IB)
3. Maintain aseptic technique for the insertion and care
of intravascular catheters. (IB)
4. Wear either clean or sterile gloves when changing the
dressing on intravascular catheters. (IC)
Disinfection of hubs and changing the access
lumens/devices
The hubs on CVCs are a common source of bacterial
colonization and serve as immediate portal of entry of
microorganisms to the intraluminal surface of the cath-
eter. These colonizers from the catheter hub and lumen
can be dispersed into the bloodstream resulting in
CLABSI. The disinfection of catheter hub surface is
therefore, critical every time before they are accessed.
1. Use a CVC with the minimum number of ports or
lumens essential for the management of the patient. (IB)
2. No recommendation can be made regarding the use
of a designated lumen for parenteral nutrition. (UI)
3. Change the needleless components at as the same
time the administration set are changed or according
to manufacturers’ recommendations for the purpose
of reducing infection rates. There is no benefit to
changing administration sets and hubs/connectors
more frequently than every 72 h. (II)
4. Ensure that all components of the system are
compatible to minimize leaks and breaks in the
system. (II)
5. Minimize contamination risk by scrubbing the access
port with an appropriate antiseptic (alcohol-based
chlorhexidine, povidone iodine, an alcohol-based
iodophor, or 70 % alcohol) and accessing the port
only with sterile devices. (IA)
6. When needleless systems are used, a split septum
valve may be preferred over some mechanical valves
due to increased risk of infection with the mechanical
valves. (II)
Proper dressing change technique
Transparent semipermeable dressings are preferred over
gauze dressings as they allow continuous visual inspec-
tion of the catheter site. However, gauze dressings can
be used if the patient is sweating or the site is bleeding
or oozing following CVC insertion.
1. Use either sterile gauze or sterile, transparent,
semipermeable dressing to cover the catheter site.
(IA)
2. If the patient is diaphoretic or if the site is bleeding or
oozing, use a gauze dressing until this is resolved. (II)
3. Replace catheter site dressing if the dressing becomes
damp, loosened, or visibly soiled. (IB)
4. Do not use topical antibiotic ointment or creams on
insertion sites, except for dialysis catheters, because of
their potential to promote fungal infections and
antimicrobial resistance. (IB)
5. Do not submerge the catheter or catheter site in
water. Showering should be permitted if precautions
can be taken to reduce the likelihood of water
reaching the catheter site (e.g., protect the catheter
and administration connections and hubs with a
waterproof cover during showering). This is because it
increases the risk of organisms being introduced into
the insertion site. (IB)
6. Replace gauze dressings as they become soiled. (II)
7. Replace transparent dressings used on CVC sites at
least every 7 days, except in those pediatric patients
in which the risk of dislodging the catheter may
outweigh the benefit of changing the dressing. (IB)
8. Replace transparent dressings used on tunneled or
implanted CVC sites no more than once per week
(unless the dressing is soiled or loose), until the
insertion site has healed. (II)
9. No recommendation can be made regarding the
necessity for any dressing on well-healed exit sites of
long-term cuffed and tunneled CVCs. (UI)
10. Ensure that catheter site care is compatible with the
catheter material. (IB)
11. Use a chlorhexidine-impregnated sponge dressing for
central venous catheters in patients older than
2 months of age if the CLABSI infection rate high
and not decreasing despite adherence to maintenance
bundle prevention measures, including education and
training. (IB)
12. Encourage patients to report any changes in their
catheter site or any new discomfort to staff. (II)
Standardize administration sets change
Administration sets are used for transfer of fluids, medi-
cines and nutrition to patient’s body. Prolonged use of
these sets increases the risk of infection. Therefore, rou-
tine change of the administration systems (primary and
secondary sets and add-on devices) is recommended.
1. In patients not receiving blood, blood products or fat
emulsions, replace administration sets that are
continuously used, including secondary sets and
add-on devices, no more frequently than at 96-h
intervals, but at least every 7 days. (IA)
2. No recommendation can be made regarding the
frequency for replacing intermittently used
administration sets. (UI)
3. No recommendation can be made regarding the
frequency for replacing needles to access implantable
ports. (UI)
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4. Replace tubing used to administer blood, blood
products, or fat emulsions (those combined with
amino acids and glucose in a 3-in-1 admixture or
infused separately) within 24 h of initiating the
infusion. (IB)
5. Replace tubing used to administer propofol infusions
every 6 or 12 hours, when the vial is changed, refer to
the manufacturer’s recommendation. (IA)
Recommendations for implementation [36–40]
A key success factor to the implementation of the cen-
tral line insertion and maintenance bundles is the adop-
tion of the model of improvement approach involving
multidisciplinary process stakeholders. The Plan-Do-
Study-Act (PDSA) methodology to conduct small-scale
tests of change in the ICU i.e. planning a test, trying it,
observing the results, and acting on what is learned; is
the scientific approach adopted in the implementation.
1. Implementation of the use of the CLABSI insertion
and maintenance bundles is best done using a
quality improvement approach with a
multidisciplinary team.
2. Build teams which include all staff involved in CVC
insertion and maintenance including local
champions.
3. Enhanced communication to share data and take
action
4. Hospital leadership and policymakers are to continue
providing support to build a culture of zero tolerance.
5. Lines of accountability need to be established to link
everyone in a hospital - from the board to frontline
staff - so that everyone has a shared understanding
of the organizations goals, knows their role in meeting
them, and receives feedback (e.g. dashboards) on how
they are performing.
6. There should be an ongoing focus on skill
development and competency assessment across the
organization.
7. Education and training programs should be assessed
for their content, relevance and impact on work
performance.
8. Although adherence to evidence-based practices
reduces inconsistencies in practice and can
significantly improve the overall quality of care,
healthcare organizations often find it difficult to
implement best practices. Thus, identifying and
removing barriers to adherence to these practices is
essential to a successful implementation of best
practices in the era of patient safety.
C. Additional measures to reduce CLABSI [41–77]
The rationale for the use of chlorhexidine antiseptic
bathing in place of soap and water bathing relates to the
patient’s resident skin flora that can enter the blood-
stream at the CVC insertion site or the extraluminal sur-
face of the catheter. Reducing skin contaminants with
chlorhexidine bathing can further reduce the risk of
CLABSI.
Similarly, a chlorhexidine-impregnated dressing is now
recommended by the Centers for Disease Control and
Prevention (grade IB) when basic prevention measures
are ineffective to decrease CLABSIs.
Additional measures to reduce infection include:
1. Chlorhexidine bathing in addition to maximal
barrier precautions and maintenance bundle
prevention measures. (IIB)
2. If the CLABSI rate is not decreasing despite
successful adherence to maintenance bundle
Table 2 APSIC central line insertion checklist
Name of patient Age Sex Unique ID
Name of Insertor Date Time Unit
Is the Indication for insertion appropriate? Yes No
Type of Central Venous Catheter Tunneled Non-Tunneled PICC line Chemoport Any other:
Emergency Procedure Yes No
The Insertion Procedure
Was sublclavian or IJ vein the site for insertion - Y/N
Has insertor and assistant performed hand hygiene procedures, either by washing hands with liquid soap and water or with
alcohol-based hand rubs (ABHR)?
Yes No
Was 70 % alcohol and >0.5 % CHG used in cleaning site of insertion? Yes No
Have both the operator and assistant practised maximal sterile barrier precautions (wearing a sterile gown, sterile gloves, and
cap and using a full body drape for patient)?
Yes No
Signature of person in-charge:
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Table 3 APSIC central line maintenance checklist




Type of Central Venous
Catheter
Tunneled Non-Tunneled PICC line Chemoport Any other:




Y N Comment: Y N Comment: Y N Comment: Y N Comment: Y N Comment: Y N Comment: Y N Comment:
date for change
in dressing, date
of IV set change
date for change
in dressing, date
of IV set change
date for change
in dressing, date
of IV set change
date for change
in dressing, date
of IV set change
date for change
in dressing, date
of IV set change
date for change
in dressing, date
of IV set change
date for change
in dressing, date
of IV set change
Is review done for need
for central line use?
Was hand hygiene
practised before all line
maintenance/access
procedures?





















prevention measures use a chlorhexidine-
impregnated dressing at the catheter site in patients
older than 2 months of age if there are no
contraindications
3. Minocycline-rifampin or chlorhexidine-silver
sulfadiazine impregnated catheters should be
considered in adult patients whose catheter dwell
time is expected to be >7 days and in units where
the CLABSI infection rate is not meeting the set
goal. (IA)
4. Patients using minocycline-rifampin or
chlorhexidine-silver sulfadiazine-impregnated
catheters should be monitored for side effects, such
as anaphylaxis (IIIB).
5. Prophylactic antimicrobial or antiseptic lock solution
should be considered for the following:
a. Patients with long-term hemodialysis catheters (IA)
b. Patients with limited venous access and a history
of recurrent CLABSI (IIB)
c. Pediatric cancer patients with long-term catheters
(IB)
6. Scrubbing the access port of connectors with an
appropriate antiseptic and accessing the port only
with sterile devices. (IA)
Surveillance
Surveillance for outcomes (CLABSI infection rates) is a pri-
mary outcome. Several centers have found it useful to
monitor adherence to evidence-based central line insertion
and maintenance practices (insertion bundle compliance
rates) as a method for identifying quality improvement
opportunities and strategically targeting interventions for
the reduction of CLABSI.
1. The CLABSI rate are calculated per 1000 central
line days
2. The Central line insertion bundle compliance rate is
calculated as a percentage of central line insertions
per month (%) [this is computed using data
collected from checklist in Table 2]
The Central line maintenance bundle compliance rate
is calculated as a percentage of central line insertions
per month (%) [This is computed using data collected
from checklist in Table 3].
Improvement takes place over time. Determining if
improvement has really occurred and if it is a lasting ef-
fect requires observing rates of infection over time. Run
charts can be used to monitor these changes. Run charts
are graphs of data over time and are one of the single
most important tools in performance improvement.
Feedback the data is best done in a timely manner to
relevant clinical groups so that targeted CLABSI prevention
and control measures can be introduced and reported on.
Conclusion
There are few reports on the CLABSI rates in hospitals
at Asia Pacific region. A recent systematic review
revealed a pooled incidence density of 4 · 7 per 1000
catheter-days (95 % CI: 2 · 9- 6 · 5; I2 = 83 · 8; χ2 n = 30 · 9,
p < 0 · 001) from 6 published studies [78]. Most ICUs in
developed countries now report CLABSI rates which are
zero or close to zero. CLABSI is one of the most
common and yet preventable healthcare associated
infections. We recommend hospitals in the Asia Pacific
region that have yet to achieve zero CLABSI rates con-
tinue surveillance of CLABSIs and implement Central
Line Insertion and Maintenance Bundles using quality
improvement approaches to improve practices as
described in the APSIC Guide For Prevention Of Central
Line Associated Bloodstream Infections (CLABSI).
Competing interests
AA was supported by the National Research University Project of the
Thailand Office of Higher Education Commission. The authors declare that
they have no competing interests.
Authors’ contributions
LML drafted the manuscript and AA did the initial editing before revised
manuscript was seen by other authors for further comments. All authors
read and approved the final manuscript.
Acknowledgement
We acknowledge support through an educational grant from Advanced
Sterilization Products, A Division of Johnson & Johnson Medical ASEAN
Endorsed by:
1. Ho Chi Minh City Infection Control Society, Vietnam
2. Hong Kong Infection Control Nursing Association (HKICNA), Hong Kong
3. Hospital Infection Society-India (HISI), India
4. Infection Control Association, Singapore [ICA(S)]
5. Nosocomial Infection Control Group of Thailand, Thailand
6. Philippines Hospital Infection Control Society (PHICS), Philippines
7. Infection Control Society of Taiwan, Taiwan
Author details
1Singapore General Hospital, Outram Road, Singapore 169608, Singapore.
2Thammasat University Hospital, Bangkok, Thailand. 3Artemis Hospital, New
Delhi, India. 4Infection Control Consultancy (ICC), Melbourne, Australia.
5Yamagata University Hospital, Yamagata, Japan. 6Cho Ray Hospital, Ho Chí
Minh, Vietnam. 7Hong Kong Baptist Hospital, Kowloon, Hong Kong. 8Chong
Hua Hospital, Cebu City, Philippines. 9West China Hospital of Sichuan
University, Chengdu, China. 10Asan Medical Center, Seoul, Korea. 11MacKay
Memorial Hospital, Taipei City, Taiwan.
Received: 14 October 2015 Accepted: 24 April 2016
References
1. The Joint Commission. Preventing Central Line–Associated Bloodstream
Infections: A Global Challenge, a Global Perspective. Oak Brook: Joint
Commission Resources; 2012.
2. Pronovost P, Needham D, Berenholtz S, Frank J, et al. An intervention to
decrease catheter-related bloodstream infections in the ICU. N Engl J Med.
2006;355(26):2725–32.
3. Datta P, Rani H, Chauhan R, Gombar S, Chander J. Health-care-associated
infections: Risk factors and epidemiology from an intensive care unit in
Northern India. Indian J Anaesth. 2014;58(1):30–5.
4. Fraenkel D, Rickard C, Thomas P, Faoagali J, George N, Ware R. A
prospective, randomized trial of rifampicin-minocycline-coated and silver-
platinum-carbon-impregnated central venous catheters. Crit Care Med.
2006;34(3):668–75.
Ling et al. Antimicrobial Resistance and Infection Control  (2016) 5:16 Page 7 of 9
5. Kim SH, Song KI, Chang JW, Kim SB, Sung SA, Jo SK, et al. Prevention of
uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock
technique: a prospective, randomized clinical trial. Kidney Int. 2006;69(1):
161–4.
6. Richards B, Chaboyer W, Bladen T, Schluter PJ. Effect of central venous
catheter type on infections: a prospective clinical trial. J Hosp Infect. 2003;
54(1):10–7.
7. Sheng WH, Ko WJ, Wang JT, Chang SC, Hsueh PR, Luh KT. Evaluation of
antiseptic-impregnated central venous catheters for prevention of catheter-
related infection in intensive care unit patients. Diagn Microbiol Infect Dis.
2000;38(1):1–5.
8. Yoshida J, Ishimaru T, Fujimoto M, Hirata N, Matsubara N, Koyanagi N. Risk
factors for central venous catheter-related bloodstream infection: a 1073-
patient study. J Infect Chemother. 2008;14(6):399–403.
9. Zhang P, Yuan J, Tan H, Lv R, Chen J. Successful prevention of cuffed
hemodialysis catheter-related infection using an antibiotic lock technique
by strictly catheter-restricted antibiotic lock solution method. Blood Purif.
2009;27(2):206–11.
10. Apisarnthanarak A, Greene MT, Kennedy EH, Khawcharoenporn T, Krein S,
Saint S. National survey of practices to prevent healthcare-associated
infections in Thailand: the role of safety culture and collaboratives. Infect
Control Hosp Epidemiol. 2012;33(7):711–7. doi:10.1086/666330. Epub 2012
May 14.
11. Apisarnthanarak A, Khawcharoenporn T, Mundy LM. National survey of
suboptimal and unnecessary practices for central line placement and
management in Thailand. Am J Infect Control. 2013;41(2):e11–3.
doi:10.1016/j.ajic.2012.07.019.
12. Jaggi N, Sissodia P. Repeated multimodal supervision programs to reduce
the central line-associated bloodstream infection rates in an Indian
corporate hospital. Healthcare Infection. 2014;19:53–8.
http://dx.doi.org/10.1071/HI13030.
13. Jaggi N, Rodrigues C, Rosenthal VD, Todi SK, Shah S, Saini N, et al. Impact of an
International Nosocomial Infection Control Consortium multidimensional
approach on central line-associated bloodstream infection rates in adult
intensive care units in eight cities in India. Int J Infect Dis. 2013;17(12):1218–24.
14. Jaggi N, Nirwan P, Naryana E, Kaur KP. The analysis and impact of three
successive intervention programmes directed to reduce central line
associated blood stream infections over a four year period in a tertiary care
hospital in India. Antimicrobial Resistance and Infection Control. 2013;2
Suppl 1:2. doi:10.1186/2047-2994-2-S1-P2.
15. Parienti J, Mongardon N, Megarbane B, Mira J, Kalfon P, Gros A, et al.
Intravascular complications of central venous catheterization by insertion
site. N Engl J Med. 2015;373:1220–9. doi:10.1056/NEJMoa1500964.
16. Parienti JJ, Thirion M, Megarbane B, et al. Femoral vs jugular venous
catheterization and risk of nosocomial events in adults requiring acute renal
replacement therapy: a randomized controlled trial. JAMA. 2008;299:2413–22.
17. Nagashima G, Kikuchi T, Tsuyuzaki H, et al. To reduce catheter-related
bloodstream infections: is the subclavian route better than the jugular route
for central venous catheterization? J Infect Chemother. 2006;12:363–5.
18. Hind D, Calvert N, McWilliams R, et al. Ultrasonic locating devices for central
venous cannulation: meta-analysis. BMJ. 2003;327:361.
19. Larson EL, Rackoff WR, Weiman M, et al. APIC guideline for handwashing and
hand antisepsis in health care settings. Am J Infect Control. 1995;23:251–69.
20. WHO Guidelines on Hand Hygiene in Health Care: a Summary 2009.
21. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-
iodine, alcohol, and chlorhexidine for prevention of infection associated
with central venous and arterial catheters. Lancet. 1991;338:339–43.
22. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared
with povidone-iodine solution for vascular catheter-site care: a meta-
analysis. Ann Intern Med. 2002;136:792–801.
23. Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-
related infections by using maximal sterile barrier precautions during
insertion. Infect Control Hosp Epidemiol. 1994;15:231–8.
24. Lin TY, Lee CM, Wang FD, et al. Taiwan guidelines for prevention and
control of intravascular catheter-related bloodstream infections. 2011.
25. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of
intravascular catheter-related infections. Clin Infect Dis. 2011;52(9):e162-93.
doi:10.1093/cid/cir257.
26. Guidelines for the Prevention of Intravascular Catheter-Related Infections,
CDC 2011 (available at: http://www.cdc.gov/hicpac/pdf/guidelines/bsi-
guidelines-2011.pdf)
27. Guide to the eliminations of catheter–related bloodstream infections- An
APIC guide 2009.
28. Getting Started Kit: Prevent Central Line Infections, Central Line Associated -
Blood Stream Infections (CLA-BSI) Safer Healthcare Now! Campaign (SHN) 2009
29. Central line insertion and maintenance guidelines. Australian Commission
on Safety and Quality in Health care 2012.
30. Camp-Sorrell D, editor. Access Device Guidelines: Recommendations for
Nursing Practice and Education. 3rd ed. Pittsburgh: Oncology Nursing
Society; 2011. Copyright 2011 by ONS. INS 2011 Infusion Nursing Standards
of Practice.
31. Basic Infection Control And Prevention Plan for Outpatient Oncology
Settings CDC December 2011
32. Guide to the Elimination of Infections in Hemodialysis, An APIC Guide 2010
33. NHMRC Australian Guidelines for the Prevention and Control of Infection in
Healthcare. Commonwealth of Australia 2010.
34. JCI. 2012. Preventing Central Line–Associated Bloodstream Infections. A
Global Challenge, A Global Perspective. Available from:
www.jointcommission.org/assets/1/18/clabsi_monograph.pdf
35. CDC. 2011 Guidelines for the Prevention of Intravascular Catheter-Related
Infections. Available from: http://www.cdc.gov/hicpac/pdf/guidelines/bsi-
guidelines-2011.pdf
36. Guide H-t. Prevent Central Line-Associated Bloodstream Infections.
Cambridge: Institute for Healthcare Improvement; 2012.
37. Weaver SJ, Lubomksi LH, Wilson RF, Pfoh ER, Martinez KA, Dy SM.
Promoting a culture of safety as a patient safety strategy: a systematic
review. Ann Intern Med. 2013;158(5 pt 2):369–74.
38. Hatler CW, Mast D, Corderella J, et al. Using evidence and process
improvement strategies to enhance healthcare outcomes for the critically ill:
a pilot project. Am J Crit Care. 2006;15(6):549–55.
39. Warye KL, Murphy DM. Targeting zero health care–associated infections. Am
J Infect Control. 2008;36:683–4.
40. Gilbert GL, Cheung PY, Kerridge IB. Infection control, ethics and
accountability. Med J Aust. 2009;190(12):696–8.
41. Marschall J, Mermel LA, Fakih M, et al. Strategies to Prevent Central Line–
Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update.
Infect Control Hosp Epidemiol. 2014;35(7):753–71.
42. Garland JS, Alex CP, Mueller CD, et al. A randomized trial comparing
povidone-iodine to a chlorhexidine gluconate-impregnated dressing for
prevention of central venous catheter infections in neonates. Pediatrics.
2001;107(6):1431–6.
43. Spencer C, Orr D, Hallam S, Tillmanns E. Daily bathing with octenidine on
an intensive care unit is associated with a lower carriage rate of meticillin-
resistant Staphylococcus aureus. J Hosp Infect. 2013;83(2):156–9.
44. Timsit JF, Schwebel C, Bouadma L, Geffroy A, Garrouste-Orgeas M, Pease S,
Herault MC, Haouache H, Calvino-Gunther S, Gestin B. Chlorhexidine-
impregnated sponges and less frequent dressing changes for prevention of
catheter-related infections in critically ill adults: a randomized controlled
trial. JAMA. 2009;301:1231–41.
45. Tamma PD, Aucott SW, Milstone AM. Chlorhexidine use in the neonatal
intensive care unit: results from a national survey. Infect Control Hosp
Epidemiol. 2010;31(8):846–9.
46. Huang EY, Chen C, Abdullah F, et al. Strategies for the prevention of central
venous catheter infections: an American Pediatric Surgical Association
Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg.
2011;46(10):2000–2011.
47. O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO,
Lipsett PA, Masur H, Mermel LA, Pearson ML, Raad II, Randolph AG, Rupp
ME, Saint S. Healthcare Infection Control Practices Advisory Committee
(HICPAC). Guidelines for the prevention of intravascular catheter-related
infections. Clin Infect Dis. 2011;52(9):e162–93. Epub 2011 Apr 1.
48. Batra R, Cooper BS, Whiteley C, Patel AK, Wyncoll D, Edgeworth JD. Efficacy
and limitation of a chlorhexidine-based decolonization strategy in
preventing transmission of methicillin-resistant Staphylococcus aureus in an
intensive care unit. Clin Infect Dis. 2010;50(2):210–7.
49. Lai NM, Chaiyakunapruk N, Lai NA, O’Riordan E, Pau WS, Saint S. Catheter
impregnation, coating or bonding for reducing central venous catheter-related
infections in adults. Cochrane Database Syst Rev. 2013;6:CD007878.
50. Hagau N, Studnicska D, Gavrus RL, Csipak G, Hagau R, Slavcovici AV. Central
venous catheter colonization and catheter-related bloodstream infections in
critically ill patients: a comparison between standard and silver-integrated
catheters. Eur J Anaesthesiol. 2009;26:752–8.
Ling et al. Antimicrobial Resistance and Infection Control  (2016) 5:16 Page 8 of 9
51. Antonelli M, De Pascale G, Ranieri VM, Pelaia P, Tufano R, Piazza O, et al.
Comparison of triple-lumen central venous catheters impregnated with
silver nanoparticles (AgTive(R)) vs conventional catheters in intensive care
unit patients. J Hosp Infect. 2012;82:101–7.
52. Weber JM, Sheridan RL, Fagan S, Ryan CM, Pasternack MS, Tompkins RG.
Incidence of catheter-associated bloodstream infection after introduction of
minocycline and rifampin antimicrobial-coated catheters in a pediatric burn
population. J Burn Care Res. 2012;33:539–43.
53. Chelliah A, Heydon KH, Zaoutis TE, Rettig SL, Dominguez TE, Lin R, et al.
Observational trial of antibiotic-coated central venous catheters in critically
ill pediatric patients. Pediatr Infect Dis J. 2007;26:816–20.
54. Bertini G, Elia S, Ceciarini F, Dani C. Reduction of catheter-related
bloodstream infections in preterm infants by the use of catheters with the
AgION antimicrobial system. Early Hum Dev. 2013;89:21–5.
55. Zhao Y, Li Z, Zhang L, Yang J, Yang Y, Tang Y, et al. Citrate versus heparin
lock for hemodialysis catheters: a systematic review and meta-analysis of
randomized controlled trials. Am J Kidney Dis. 2014;63:479–90.
56. Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M.
Antimicrobial lock solutions for the prevention of infections associated with
intravascular catheters in patients undergoing hemodialysis: systematic
review and meta-analysis of randomized, controlled trials. Clin Infect Dis.
2008;47:83–93.
57. Jaffer Y, Selby NM, Taal MW, Fluck RJ, McIntyre CW. A meta-analysis of
hemodialysis catheter locking solutions in the prevention of catheter-
related infection. Am J Kidney Dis. 2008;51:233–41.
58. Labriola L, Crott R, Jadoul M. Preventing haemodialysis catheter-related
bacteraemia with an antimicrobial lock solution: a meta-analysis of
prospective randomized trials. Nephrol Dial Transplant. 2008;23:1666–72.
59. Snaterse M, Ruger W, Scholte Op Reimer WJ, Lucas C. Antibiotic-based
catheter lock solutions for prevention of catheter-related bloodstream
infection: a systematic review of randomised controlled trials. J Hosp Infect.
2010;75:1–11.
60. Zacharioudakis IM, Zervou FN, Arvanitis M, Ziakas PD, Mermel LA, Mylonakis
E. Antimicrobial lock solutions as a method to prevent central line-
associated bloodstream infections: a meta-analysis of randomized controlled
trials. Clin Infect Dis. 2014. doi:10.1093/cid/ciu671.
61. van de Wetering MD, van Woensel JB, Lawrie TA. Prophylactic antibiotics for
preventing Gram positive infections associated with long-term central
venous catheters in oncology patients. Cochrane Database Syst Rev. 2013;
11:CD003295.
62. Catheter WM. Llubrication and fixation: interventions. Br J Nurs. 2013;22(10):
566. 568-9.
63. Alekseyev S, Byrne M, Carpenter A, Franker C, Kidd C, Hulton L. Prolonging
the life of a patient’s IV: an integrative review of intravenous securement
devices. Medsurg Nurs. 2012;21(5):285–92.
64. Petree C, Wright DL, Sanders V, Killion JB. Reducing blood stream infections
during catheter insertion. Radiol Technol. 2012;83(6):532–40.
65. Cotogni P, Pittiruti M, Barbero C, Monge T, Palmo A, Boggio Bertinet D.
Catheter-related complications in cancer patients on home parenteral
nutrition: a prospective study of over 51,000 catheter days. JPEN J Parenter
Enteral Nutr. 2013;37(3):375–83.
66. Christopher C, Maki DG. The Promise of Novel Technology for the
Prevention of Intravascular Device–Related Bloodstream Infection. Clin Infect
Dis. 2002;34(10):1362–8. Epub 2002 Apr 17.
67. Simonova G, Rickard CM, Dunster KR, Smyth DJ, McMillan D, Fraser JF.
Cyanoacrylate tissue adhesives - effective securement technique for
intravascular catheters: in vitro testing of safety and feasibility. Anaesth
Intensive Care. 2012;40(3):460–6.
68. Egan GM, Siskin GP, Weinmann 4th R, Galloway MM. A prospective
postmarket study to evaluate the safety and efficacy of a new peripherally
inserted central catheter stabilization system. J Infus Nurs. 2013;36(3):181–8.
69. Sundararajan K, Wills S, Chacko B, Kanabar G, O’Connor S, Deane A. Impact
of delirium and suture-less securement on accidental vascular catheter
removal in the ICU. Anaesth Intensive Care. 2014;42(4):473–9.
70. Rupp ME, Sholtz LA, Jourdan DR, et al. Outbreak of bloodstream infection
temporally associated with the use of an intravascular needleless valve. Clin
Infect Dis. 2007;44:1408–14.
71. Maragakis LL, Bradley KL, Song X, et al. Increased catheter-related bloodstream
infection rates after the introduction of a new mechanical valve intravenous
access port. Infect Control Hosp Epidemiol. 2006;27(1):67–70.
72. Mazher MA, Kallen A, Edwards JR, Donlan RM. An in vitro evaluation of
disinfection protocols used for needleless connectors of central venous
catheters. Lett Appl Microbiol. 2013;57(4):282–7. doi:10.1111/lam.12108.
Epub 2013 Jun 7.
73. Pichler J, Soothill J, Hill S. Reduction of blood stream infections in children
following a change to chlorhexidine disinfection of parenteral nutrition
catheter connectors. Clin Nutr. 2014;33(1):85–9. doi:10.1016/j.clnu.2013.03.
021. Epub 2013 Apr 10.
74. Casey AL, Karpanen TJ, Nightingale P, Cook M, Elliott TS. Microbiological
comparison of a silver-coated and a non-coated needleless intravascular
connector in clinical use. J Hosp Infect. 2012;80(4):299–303. doi:10.1016/j.
jhin.2012.01.005. Epub 2012 Feb 17.
75. Menyhay SZ, Maki DG. Preventing central venous catheter-associated
bloodstream infections: development of an antiseptic barrier cap for
needleless connectors. Am J Infect Control. 2008;36(10):S174. doi:10.1016/j.
ajic.2008.10.006. e1-5.
76. Sweet MA, Cumpston A, Briggs F, Craig M, Hamadani M. Impact of alcohol-
impregnated port protectors and needleless neutral pressure connectors on
central line-associated bloodstream infections and contamination of blood
cultures in an inpatient oncology unit. Am J Infect Control. 2012;40(10):931–4.
doi:10.1016/j.ajic.2012.01.025. Epub 2012 May 9.
77. Sandora TJ, Graham DA, Conway M, Dodson B, Potter-Bynoe G, Margossian
SP. Impact of needleless connector change frequency on central line-
associated bloodstream infection rate. Am J Infect Control. 2014;42(5):485–9.
doi:10.1016/j.ajic.2014.01.022.
78. Ling ML, Apisarnthanarak A, Madriaga G. The burden of healthcare-
associated infections in Southeast Asia: A systematic literature review and
meta-analysis. Clinical Infectious Diseases 2015: civ095v1-civ095
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ling et al. Antimicrobial Resistance and Infection Control  (2016) 5:16 Page 9 of 9
